England leads in offering 'Trojan horse' drug to blood cancer patients

Blenrep is given with other meds (like bortezomib or pomalidomide plus dexamethasone) to adults whose cancer has come back after earlier treatments. Recent trials found it helps patients live longer and keeps the disease from progressing better than some current options.

Blenrep targets a marker on myeloma cells (BCMA) and delivers a powerful anti-cancer agent right where it's needed. This targeted approach is raising the bar for treating tough cases of multiple myeloma.